Zevra Therapeutics Announces Board and Executive Changes
Ticker: ZVRA · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Zevra Therapeutics shakes up board and exec pay on Dec 11, 2025.
AI Summary
On December 11, 2025, Zevra Therapeutics, Inc. announced changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans for key executives. Specific details regarding the financial impact of these changes are not provided in this initial filing.
Why It Matters
Changes in leadership and compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect future strategy and performance.
Key Players & Entities
- Zevra Therapeutics, Inc. (company) — Registrant
- December 11, 2025 (date) — Date of Earliest Event Reported
- 1180 Celebration Boulevard, Suite 103 (address) — Business and Mail Address
- Celebration, FL 34747 (address) — Business and Mail Address City/State/Zip
- Kempharm, Inc (company) — Former Company Name
FAQ
What specific roles have been affected by the departure of directors or officers?
The filing indicates the departure of certain officers and directors, but does not specify the exact roles in this section.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in this summary.
What are the key changes in compensatory arrangements for officers?
The filing notes updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not provided here.
When was the company formerly known as Kempharm, Inc.?
The company was formerly known as Kempharm, Inc. with a date of name change in 20130530 and previously in 20080507.
What is the primary business of Zevra Therapeutics, Inc.?
Zevra Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-12-17 16:15:39
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ZVRA The Nasdaq Stock Market
Filing Documents
- zvra-20251211.htm (8-K) — 27KB
- 0001434647-25-000018.txt ( ) — 139KB
- zvra-20251211.xsd (EX-101.SCH) — 2KB
- zvra-20251211_lab.xml (EX-101.LAB) — 21KB
- zvra-20251211_pre.xml (EX-101.PRE) — 12KB
- zvra-20251211_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Zevra Therapeutics, Inc. Date: December 17, 2025 By: /s/ Timothy J. Sangiovanni Timothy J. Sangiovanni, CPA Senior Vice President, Finance and Corporate Controller